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Purpose of study
Reductions in bone mineral density may occur secondary
to HIV per se or antiretroviral therapy; bone toxicity may
differ by NRTI backbone. We analysed makers of bone
turnover in patients stable on ABC or TDF containing reg-
imens.
Methods
Prospective, cross-sectional, single-centre study of indi-
viduals stable for >6 months on ABC- or TDF-based regi-
mens (naïve to TDF and ABC respectively) and <50 cps/
ml. The study was designed to measure marker of renal
and bone function. The serum bone markers were quanti-
fied: alkaline phosphatase (ALP; specific and therefore
total ALP are useful markers of bone turnover, specifically
resorption), beta crosslaps (measure of type I collagen
degradation fragments, a marker of osteoclast activity or
bone resorption) and osteocalcin (a polypeptide secreted
by osteoblasts, a marker of bone formation). Parameters
independently, significantly associated with changes in
these markers by univariate analysis (p < 0.15) were
entered into a multivariable regression model.
Summary of results
391 subjects (145 on ABC, 246 on TDF) were recruited to.
Most were male (95% on ABC, 92% on TDF); median age
(48 vs. 46 years; p = 0.021) and CD4 count (552 vs. 475;
p = 0.007) were higher in ABC recipients. Regarding mark-
ers of bone turnover 3 patients (2%) on ABC and 12 (5%)
on TDF had elevated ALP (≤162.5); OR for elevated ALP
was 0.41 on ABC but – this was not statistically significant
(p = 0.167), only elevated creatinine (>104 vs. <84; p =
0.048) was significantly associated with elevated ALP by
univariable analysis. There was a trend to more frequent
ALP elevation in females (OR 3.34; p = 0.075) and
patients in the lowest quartile for beta crosslaps were less
likely to experience an elevated ALP (OR 0.12 for ≤0.22 vs.
>0/56; p = 0.047). 9 subjects on ABC and 38 on TDF (6%
& 15% respectively) has elevated osteocalcin (>34.5). By
multivariable modelling, factors associated with elevated
osteocalcin were: TDF use (OR on ABC 0.01; p = 0.039),
elevated cystatin c (OR for 0.68 vs. >0.86 0.03; p = 0.005),
higher beta crosslaps (<0.34 vs. >0.56; p < 0.002) and low
LDL-cholesterol (OR for ≤2.40 vs. >3.57 0.02; p = 0.003).
No significant differences were observed in frequency of
hypophosphataemia.
Conclusion
Abnormalities in markers of bone turnover were infre-
quent but more common on TDF than ABC. There was no
association between altered bone markers and duration of
TDF use but the clinical impact of these changes should be
assessed longitudinally.
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